Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Phase 1 Study of MK-6482 as Monotherapy and in Combination With Lenvatinib (MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma

Next Previous
X
Search
Trial Profile

An Open-Label, Phase 1 Study of MK-6482 as Monotherapy and in Combination With Lenvatinib (MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Belzutifan (Primary) ; Lenvatinib (Primary) ; Pembrolizumab (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Merck Sharp & Dohme Corp.

    • Most Recent Events

    • 04 Jun 2024 Results (n=24; as of 29 Aug 2023) of preliminary analysis from cohort 1 presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 26 Jan 2023 Status changed from recruiting to active, no longer recruiting.
    • 14 Dec 2022 Planned End Date changed from 28 Dec 2023 to 21 Oct 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top